<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01800058</url>
  </required_header>
  <id_info>
    <org_study_id>CaPr-RTCTC-01/PI 197</org_study_id>
    <nct_id>NCT01800058</nct_id>
  </id_info>
  <brief_title>Prognostic Value of the Levels of CTCs in Peripheral Blood in Patients With Prostate Cancer at High Risk (Clinical Stages IIB-III) Treated Radically With Radiotherapy and Hormone Therapy.</brief_title>
  <official_title>Prognostic Value of the Levels of Circulating Tumor Cells (CTCs) in Peripheral Blood in Patients With Prostate Cancer at High Risk (Clinical Stages IIB-III) Treated Radically With Radiotherapy and Hormone Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The detection and quantification of Circulating tumor cells CTCs in peripheral blood of
      patients with prostate adenocarcinoma may be useful at least for:

      Getting a correct stratification of patients with high-risk prostate cancer (PCa).

      Set the prognosis at baseline. Evaluate the response to different treatments (predictive
      value and monitoring).

      Establish individualized therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective analysis of biologic samples from peripheral blood of 65 patients with localized
      high-risk PCa (NCCN 2011) treated with RTC-3D-IMRT combined with AD.

      Following the sign of the informed consent of the patient, the blood samples will be analyzed
      for CTCs using an immunomagnetic method based on the CellSearch system (Veridex), in 3
      periods of time:

        1. prior to any treatment;

        2. following AD and prior to RT; and

        3. following the end of RT (1-3 months afterwards). Comparison between the expression of
           CTCs in peripheral blood before and following AD and RT will be performed. The
           quantification of the CTCs obtained in these phases of treatment will be correlated with
           the treatment results in terms of biochemical failure according to Phoenix definition,
           distant metastasis rate and overall survival to identify a significant prognostic
           relationship and to determine the potential effect of the treatment in the number of
           CTCs Our working group will include 65 patients because the amount is based on routine
           clinical activity can be safely enrolled in the project development time by the
           participating centers.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>expression of circulating tumor cells in the peripheral blood in the peripheral blood of patients with high-risk prostate cancer (NCCN 2011)</measure>
    <time_frame>Following the end of radiotherapy (1-3 months afterwards).</time_frame>
    <description>(Initially a cutoff point of &gt; 3 or more circulating cells per 7.5 ml of blood will be taken as the reference baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiation dose</measure>
    <time_frame>Following the end of radiotherapy (1-3 months afterwards).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration and type of hormone therapy</measure>
    <time_frame>Following the end of radiotherapy (1-3 months afterwards).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gleason sum;</measure>
    <time_frame>Following the end of radiotherapy (1-3 months afterwards).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pretreatment PSA;</measure>
    <time_frame>Following the end of radiotherapy (1-3 months afterwards).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical T stage</measure>
    <time_frame>Following the end of radiotherapy (1-3 months afterwards).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical failure-free survival;</measure>
    <time_frame>Following the end of radiotherapy (1-3 months afterwards).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival defined as death due to any cause;</measure>
    <time_frame>Following the end of radiotherapy (1-3 months afterwards).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival</measure>
    <time_frame>Following the end of radiotherapy (1-3 months afterwards).</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Patients With High-risk Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Circulating prostatic tumor cells in the peripheral blood</arm_group_label>
    <description>Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):
prior to any treatment;
following AD and prior to RT; and
following the end of RT (1-3 months afterwards).
The quantification of CTC in blood samples will be done with the CellSearch® system.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Prospective analysis of biological material from samples of peripheral blood (PB) of patients
      diagnosed with prostate cancer at high risk (NCCN 2011), AJCC stage IIB-III, treated with
      3D-CRT, IMRT dose escalation (with androgen deprivation (DA))

      The sampling of peripheral blood (PB) for detection of CTCs in three treatment periods:

        -  Before starting any treatment-DA initially neoadjuvant

        -  Prior to the start of RT (DA after neoadjuvant)

        -  At the end of RT (1-3 months) The analysis-quantification of CTCs obtained in these
           phases, will correlate with treatment outcomes in terms of biochemical failure (BF)
           according to the criteria of Phoenix 2006 and overall survival and metastasis-free to
           identify potential prognostic value. Likewise determinations are compared before and
           after CTCs DA and RT to evaluate the effect of such treatments on modular quantifying
           CTCs (predictive value).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with prostate cancer at high risk (NCCN 2011), AJCC stage IIB-III,
        treated with 3D-CRT, IMRT dose escalation (with androgen deprivation (DA))
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged &gt; 18 with capacity to give informed consent.

          -  Patients with histologically confirmed prostate cancer.

          -  Patients with a high risk factor: PSA&gt; 20 ng / ml, Gleason 8-10 and / or stage T3a-b,
             N0M0 (NCCN 2011, stage IIB-III AJCC classification 2010). Staging by:
             Histology-Gleason score-, PSA, TR, ECO TR, CT, MRI.

          -  Patients who accept radical treatment with radiotherapy.

          -  Patients who give written informed consent to participate in the study

        Exclusion Criteria:

          -  Any patient diagnosed with prostate cancer, which does not meet the prerequisites.

          -  Any patients with another malignancy diagnosed in the past 5 years (except basal cell
             or squamous cell carcinoma of skin).

          -  Any patient who has prostate biopsy performed 7 days prior to study entry.

          -  Patients who have received prior treatment with hormonal therapy, chemotherapy or
             radiotherapy.

          -  Patients with PSA&gt; 100 ng / ml.

          -  Any situation or condition of the patient which in the opinion of the investigator,
             advised against participation in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Almudena Zapatero, MD, PhD, PI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Oncology Department_Hospital Universitario de La Princesa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Almudena Zapatero, MD, PhD; PI</last_name>
    <phone>+34915202315</phone>
    <email>almudena.zapatero@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Almudena Zapatero, MD</last_name>
      <phone>+34915202315</phone>
    </contact>
    <investigator>
      <last_name>Antonio Gómez Caamaño, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis León, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Almudena Zapatero, MD PhD</last_name>
      <phone>+34915202315</phone>
      <email>azapatero.hlpr@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Almudena Zapatero, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Olivier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Martín de Vidales, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Almudena Zapatero, MD</last_name>
      <phone>+34915202315</phone>
    </contact>
    <investigator>
      <last_name>María Ángeles Cabeza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfredo Rodríguez Antolín, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005 Apr;65(4):713-8.</citation>
    <PMID>15833514</PMID>
  </reference>
  <reference>
    <citation>Bolla M, Collette L, Van Tienhoven G, et al. Ten-year results of long-term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: A phase III EORTC study. Int J Radiat Oncol Biol Phys 2008;72:S30-S31.</citation>
  </reference>
  <reference>
    <citation>L. Resel Folkersma, C. Olivier Gómez, L. San José Manso, et al. Cuantificación Inmunomagnética De Células Tumorales Circulantes En Pacientes Con Cáncer De Próstata: Correlación Clínica Y Patológica. Arch. Esp. Urol. 2010; 63 (1): 23-31</citation>
  </reference>
  <results_reference>
    <citation>Damber JE, Aus G. Prostate cancer. Lancet. 2008 May 17;371(9625):1710-21. doi: 10.1016/S0140-6736(08)60729-1. Review.</citation>
    <PMID>18486743</PMID>
  </results_reference>
  <results_reference>
    <citation>Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, Park J, Shippy A. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1028-33. doi: 10.1016/j.ijrobp.2007.11.066. Epub 2008 Feb 14.</citation>
    <PMID>18280056</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74. Epub 2007 Aug 31.</citation>
    <PMID>17765406</PMID>
  </results_reference>
  <results_reference>
    <citation>Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008 Feb 1;26(4):585-91. doi: 10.1200/JCO.2007.13.9881. Epub 2008 Jan 2.</citation>
    <PMID>18172188</PMID>
  </results_reference>
  <results_reference>
    <citation>Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008 May 20;26(15):2497-504. doi: 10.1200/JCO.2007.14.9021. Epub 2008 Apr 14.</citation>
    <PMID>18413638</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007 Apr 1;13(7):2023-9.</citation>
    <PMID>17404082</PMID>
  </results_reference>
  <results_reference>
    <citation>Zapatero A, Ríos P, Marín A, Mínguez R, García-Vicente F. Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation? Clin Oncol (R Coll Radiol). 2006 Oct;18(8):600-7.</citation>
    <PMID>17051950</PMID>
  </results_reference>
  <results_reference>
    <citation>Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, Meng S, Morrison L, Tucker T, Lane N, Ghadimi BM, Heselmeyer-Haddad K, Ried T, Rao C, Uhr J. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res. 2002 Jul;8(7):2073-84.</citation>
    <PMID>12114406</PMID>
  </results_reference>
  <results_reference>
    <citation>Zapatero A, Mínguez R, Nieto S, Martín de Vidales C, García-Vicente F. Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us? Eur Urol. 2009 Apr;55(4):902-9. doi: 10.1016/j.eururo.2008.04.076. Epub 2008 May 7.</citation>
    <PMID>18485578</PMID>
  </results_reference>
  <results_reference>
    <citation>Zapatero A, García-Vicente F, Martín de Vidales C, Cruz Conde A, Ibáñez Y, Fernández I, Rabadán M. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease? Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1279-85. doi: 10.1016/j.ijrobp.2010.07.1975. Epub 2010 Oct 6.</citation>
    <PMID>20932659</PMID>
  </results_reference>
  <results_reference>
    <citation>Olivier Gómez C, Carballido Rodríguez J. [Circulating tumor cells: isolation, quantification, and relevance of their translation into clinical practice]. Actas Urol Esp. 2010 Jan;34(1):3-5. Spanish.</citation>
    <PMID>20223125</PMID>
  </results_reference>
  <results_reference>
    <citation>Alix-Panabières C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res. 2008 Aug 15;14(16):5013-21. doi: 10.1158/1078-0432.CCR-07-5125. Review.</citation>
    <PMID>18698019</PMID>
  </results_reference>
  <results_reference>
    <citation>Mocellin S, Keilholz U, Rossi CR, Nitti D. Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol Med. 2006 Mar;12(3):130-9. Epub 2006 Feb 20. Review.</citation>
    <PMID>16488189</PMID>
  </results_reference>
  <results_reference>
    <citation>Cabanes A, Vidal E, Aragonés N, Pérez-Gómez B, Pollán M, Lope V, López-Abente G. Cancer mortality trends in Spain: 1980-2007. Ann Oncol. 2010 May;21 Suppl 3:iii14-20. doi: 10.1093/annonc/mdq089.</citation>
    <PMID>20427355</PMID>
  </results_reference>
  <results_reference>
    <citation>Ghossein RA, Bhattacharya S. Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. Eur J Cancer. 2000 Aug;36(13 Spec No):1681-94. Review.</citation>
    <PMID>10959054</PMID>
  </results_reference>
  <results_reference>
    <citation>Llanes L, Ferruelo A, Luján M, Pascual C, García-Mediero JM, Berenguer A. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 2005;8(3):248-52.</citation>
    <PMID>15897916</PMID>
  </results_reference>
  <results_reference>
    <citation>Zapatero A, Valcárcel F, Calvo FA, Algás R, Béjar A, Maldonado J, Villá S. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol. 2005 Sep 20;23(27):6561-8.</citation>
    <PMID>16170164</PMID>
  </results_reference>
  <results_reference>
    <citation>Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74.</citation>
    <PMID>16798415</PMID>
  </results_reference>
  <results_reference>
    <citation>Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 2006 Jun;33(3 Suppl 9):S9-14. Review.</citation>
    <PMID>16797376</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2013</study_first_submitted>
  <study_first_submitted_qc>February 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2013</study_first_posted>
  <last_update_submitted>February 25, 2013</last_update_submitted>
  <last_update_submitted_qc>February 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

